文献速递神经肿瘤

WHO I级颅底脑膜瘤次全切除术后辅助放疗与观察及挽救性放疗的比较:倾向性评分校正分析

Comparison of adjuvant radiation versus observation and salvage radiation after subtotal resection of a WHO grade I skull base meningioma: a propensity score-adjusted analysis.
PubMed 文献 · J Neurooncol · 2025-02-25

本研究纳入1995年至2021年间新诊断的WHO I级颅底脑膜瘤且影像学确认次全切除的患者179例,其中25例(14.0%)接受辅助放疗,154例观察。观察组中90例(58.4%)出现肿瘤进展,64例(71.1%)接受挽救性放疗。经倾向性评分和逆概率治疗加权校正的Cox回归显示,观察加挽救性放疗较辅助放疗显著延长放疗失败无生存期(HR=0.06,p=0.013;HR=0.08,p=0.026)。作者认为,经过适当选择的患者可以观察并密切随访,将放疗保留用于进展时。

要点

  • 次全切除术后10年内多数患者出现肿瘤进展。
  • 观察加挽救性放疗较辅助放疗显著延长放疗失败无生存期。
  • 作者认为经适当选择的患者可观察并密切随访,放疗留待进展时使用。

核心结论

  • 大多数患者在次全切除术后10年内出现肿瘤进展。
  • 本研究数据提示,经过适当选择的患者可以观察并密切随访,将放疗保留用于肿瘤进展时。

研究设计与样本

  • 纳入1995年至2021年间新诊断的WHO I级颅底脑膜瘤且影像学确认次全切除的患者。
  • 共179例患者,其中25例(14.0%)接受辅助放疗,154例观察。
  • 采用多变量Cox回归,校正倾向性评分和逆概率治疗加权。

主要发现

  • 观察组154例中,90例(58.4%)出现肿瘤进展,64例(71.1%)接受挽救性放疗。
  • 观察组3年、5年、10年无进展生存率分别为60.6%、47.5%、26.8%。
  • 辅助放疗组3年、5年、10年无进展生存率/放疗失败无生存率均为84.2%、77.2%、77.2%。
  • 挽救性放疗组3年、5年、10年无进展生存率分别为96.0%、85.0%、80.0%。
  • 观察加挽救性放疗组3年、5年、10年放疗失败无生存率分别为100%、97.7%、92.8%。

关键数值与推荐

  • 校正残余肿瘤体积后,倾向性评分Cox模型显示观察加挽救性放疗较辅助放疗显著延长放疗失败无生存期(HR=0.06,p=0.013)。
  • 逆概率治疗加权Cox模型显示观察加挽救性放疗较辅助放疗显著延长放疗失败无生存期(HR=0.08,p=0.026)。
  • 中位随访时间为77.5个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In patients with subtotal resection (STR) of WHO grade I skull base meningiomas, treatment strategies of adjuvant radiation versus observation with salvage radiation, if necessary, were compared using progression-free survival (PFS) and radiation failure-free survival (RFFS). METHODS: Patients with newly diagnosed WHO grade I skull base meningioma who underwent radiographically confirmed STR between 1995 and 2021 were included. PFS was measured from last treatment date. RFFS was measured from surgery date to first radiation failure. Multivariable Cox regression, adjusted for propensity score (PS) and inverse probability treatment weighted (IPTW), was performed. RESULTS: Of 179 patients, 25 (14.0%) received adjuvant radiation. Among 154 observed patients, 90 (58.4%) experienced tumor progression and 64 (71.1%) received salvage radiation. Observation after STR had PFS at 3, 5, and 10 years of 60.6%, 47.5%, and 26.8%, respectively. Adjuvant radiation had PFS/RFFS at 3, 5, and 10 years of 84.2%, 77.2%, and 77.2%. Salvage radiation had PFS at 3, 5, and 10 years of 96.0%, 85.0%, and 80.0%. RFFS after observation with salvage radiation, if needed, at 3, 5, and 10 years was 100%, 97.7%, and 92.8%. PS and IPTW Cox regression models, controlling for residual tumor volume, demonstrated that observation with salvage radiation significantly prolonged RFFS (HR = 0.06, p = 0.013; HR 0.08, p = 0.026, respectively) compared to adjuvant radiation. Median follow-up was 77.5 months. CONCLUSION: Most patients will have tumor progression within 10 years of STR. Our data suggests that appropriately selected patients can be observed with close follow-up, reserving radiation for progression.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Kosanam AR, Ma J, White AJ, et al. Comparison of adjuvant radiation versus observation and salvage radiation after subtotal resection of a WHO grade I skull base meningioma: a propensity score-adjusted analysis. J Neurooncol. 2025. PMID: 39998721. doi:10.1007/s11060-025-04980-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。